$ENTX
Entera Bio Ltd

2023 Q2 Form 10-Q Financial Statement

#000117891323001715 Filed on May 05, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $0.00 $0.00 $68.00K
YoY Change -100.0% -100.0% -57.5%
Cost Of Revenue $0.00 $0.00 $54.00K
YoY Change -100.0% -100.0% -10.0%
Gross Profit $0.00 $0.00 $14.00K
YoY Change -100.0% -100.0% -86.0%
Gross Profit Margin 20.59%
Selling, General & Admin $1.135M $1.294M $2.171M
YoY Change -39.63% -40.4% 65.73%
% of Gross Profit 15507.14%
Research & Development $1.209M $931.0K $1.690M
YoY Change -13.27% -44.91% 45.69%
% of Gross Profit 12071.43%
Depreciation & Amortization $15.00K $14.00K $16.00K
YoY Change -6.25% -12.5% -82.22%
% of Gross Profit 114.29%
Operating Expenses $2.330M $2.212M $3.849M
YoY Change -28.53% -42.53% 56.46%
Operating Profit -$2.330M -$2.212M -$3.835M
YoY Change -28.29% -42.32% 62.5%
Interest Expense $5.000K $22.00K $44.00K
YoY Change -91.67% -50.0% -100.62%
% of Operating Profit
Other Income/Expense, Net $5.000K $22.00K $44.00K
YoY Change -91.67% -50.0% 340.0%
Pretax Income -$2.325M -$2.190M -$3.791M
YoY Change -27.09% -42.23% -59.88%
Income Tax $0.00 $0.00 -$7.000K
% Of Pretax Income
Net Earnings -$2.325M -$2.190M -$3.784M
YoY Change -27.0% -42.12% 64.81%
Net Earnings / Revenue -5564.71%
Basic Earnings Per Share $0.08 $0.08 $0.13
Diluted Earnings Per Share $0.08 $0.08 -$131.4K
COMMON SHARES
Basic Shares Outstanding 28.81M shares 28.81M shares 28.80M shares
Diluted Shares Outstanding 28.81M shares 28.81M shares 28.80M shares

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.135M $10.69M $20.11M
YoY Change -47.13% -46.83% 22.77%
Cash & Equivalents $9.135M $10.69M $20.11M
Short-Term Investments
Other Short-Term Assets $354.0K $653.0K $1.322M
YoY Change -61.61% -50.61% 27.12%
Inventory
Prepaid Expenses $296.0K
Receivables $29.00K $29.00K $210.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $9.814M $11.37M $21.64M
YoY Change -46.74% -47.45% 24.16%
LONG-TERM ASSETS
Property, Plant & Equipment $122.0K $136.0K $163.0K
YoY Change -26.51% -16.56% -66.73%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $49.00K $49.00K $296.0K
YoY Change -84.97% -83.45%
Total Long-Term Assets $631.0K $233.0K $671.0K
YoY Change -4.68% -65.28% -39.0%
TOTAL ASSETS
Total Short-Term Assets $9.814M $11.37M $21.64M
Total Long-Term Assets $631.0K $233.0K $671.0K
Total Assets $10.45M $11.61M $22.31M
YoY Change -45.28% -47.98% 20.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $240.0K $150.0K $199.0K
YoY Change 120.18% -24.62% -54.77%
Accrued Expenses $1.625M $1.344M $1.975M
YoY Change 3.97% -31.95%
Deferred Revenue $0.00
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.865M $1.494M $2.334M
YoY Change 10.22% -35.99% -78.02%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $348.0K $32.00K $233.0K
YoY Change 174.02% -86.27% 191.25%
Total Long-Term Liabilities $348.0K $32.00K $233.0K
YoY Change 174.02% -86.27% -22.33%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.865M $1.494M $2.334M
Total Long-Term Liabilities $348.0K $32.00K $233.0K
Total Liabilities $2.213M $1.526M $2.567M
YoY Change 21.66% -40.55% -76.47%
SHAREHOLDERS EQUITY
Retained Earnings -$100.0M -$97.69M -$86.20M
YoY Change 11.86% 13.33%
Common Stock $108.2M $107.7M $105.9M
YoY Change 1.48% 1.71%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $8.232M $10.08M $19.75M
YoY Change
Total Liabilities & Shareholders Equity $10.45M $11.61M $22.31M
YoY Change -45.28% -47.98% 20.41%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$2.325M -$2.190M -$3.784M
YoY Change -27.0% -42.12% 64.81%
Depreciation, Depletion And Amortization $15.00K $14.00K $16.00K
YoY Change -6.25% -12.5% -82.22%
Cash From Operating Activities -$1.559M -$1.609M -$4.792M
YoY Change -44.85% -66.42% 110.18%
INVESTING ACTIVITIES
Capital Expenditures $1.000K $11.00K -$23.00K
YoY Change -105.26% -147.83%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$1.000K -$11.00K -$23.00K
YoY Change -94.74% -52.17%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.000K 0.000 0.000
YoY Change -61.54% -100.0%
NET CHANGE
Cash From Operating Activities -1.559M -$1.609M -4.792M
Cash From Investing Activities -1.000K -$11.00K -23.00K
Cash From Financing Activities 5.000K 0.000 0.000
Net Change In Cash -1.555M -$1.620M -4.815M
YoY Change -45.11% -66.36% -161.89%
FREE CASH FLOW
Cash From Operating Activities -$1.559M -$1.609M -$4.792M
Capital Expenditures $1.000K $11.00K -$23.00K
Free Cash Flow -$1.560M -$1.620M -$4.769M
YoY Change -44.44% -66.03% 109.17%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Security12b Title
Security12bTitle
Ordinary Shares
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
ENTERA BIO LTD.
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
516000 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-97700000 usd
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6238605 shares
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28809922 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28809922 shares
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
2212000 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
3849000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2212000 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3835000 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
22000 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2190000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3784000 usd
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28809922 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28804411 shares
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7116583 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
0.73
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.74
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0398
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y3M18D
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1233000 usd

Files In Submission

Name View Source Status
entx-20230331_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
entx-20230331_cal.xml Edgar Link unprocessable
entx-20230331_pre.xml Edgar Link unprocessable
0001178913-23-001715-index-headers.html Edgar Link pending
0001178913-23-001715-index.html Edgar Link pending
0001178913-23-001715.txt Edgar Link pending
0001178913-23-001715-xbrl.zip Edgar Link pending
entx-20230331.xsd Edgar Link pending
exhibit_31-1.htm Edgar Link pending
exhibit_31-2.htm Edgar Link pending
exhibit_32-1.htm Edgar Link pending
exhibit_32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
entx-20230331_def.xml Edgar Link unprocessable
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
zk2329583.htm Edgar Link pending
zk2329583_htm.xml Edgar Link completed